切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2017, Vol. 06 ›› Issue (06) : 494 -498. doi: 10.3877/cma.j.issn.2095-3232.2017.06.017

所属专题: 文献

临床研究

合并肝硬化的小肝内胆管细胞癌MRI强化特征分析和鉴别诊断
伍路1, 黄彬1, 霍雷1, 夏勇1, 闫振林1, 沈锋1,()   
  1. 1. 200438 上海,第二军医大学附属东方肝胆外科医院肝脏外科
  • 收稿日期:2017-08-23 出版日期:2017-12-10
  • 通信作者: 沈锋
  • 基金资助:
    国家自然基金委创新群体项目(81521091); 国家自然科学基金(81301302); 上海市科委西医引导项目(15411988100)

MRI enhancement features and differential diagnosis of small intrahepatic cholangiocarcinoma with liver cirrhosis

Lu Wu1, Bin Huang1, Lei Huo1, Yong Xia1, Zhenlin Yan1, Feng Shen1,()   

  1. 1. Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital Affiliated to the Second Military Medical University, Shanghai 200438, China
  • Received:2017-08-23 Published:2017-12-10
  • Corresponding author: Feng Shen
  • About author:
    Corresponding author: Shen Feng, Email:
引用本文:

伍路, 黄彬, 霍雷, 夏勇, 闫振林, 沈锋. 合并肝硬化的小肝内胆管细胞癌MRI强化特征分析和鉴别诊断[J]. 中华肝脏外科手术学电子杂志, 2017, 06(06): 494-498.

Lu Wu, Bin Huang, Lei Huo, Yong Xia, Zhenlin Yan, Feng Shen. MRI enhancement features and differential diagnosis of small intrahepatic cholangiocarcinoma with liver cirrhosis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2017, 06(06): 494-498.

目的

探讨合并肝硬化的小肝内胆管细胞癌(ICC)的MRI强化特征和鉴别诊断。

方法

本前瞻性队列研究对象为2012年12月至2015年12月在第二军医大学附属东方肝胆外科医院接受外科手术治疗的56例合并肝硬化的小ICC患者。其中男40例,女16例;年龄29~74岁,中位年龄54岁。患者均签署知情同意书,符合医学伦理学规定。患者行肝脏动态增强MRI检查,静脉注射钆喷酸葡胺造影剂。增强MRI扫描包括肝动脉期、门静脉期和延迟期。采用kappa系数评估观察者间判读强化类型的一致性。强化类型与病灶直径相关性分析采用Fisher确切概率法。

结果

观察者对病灶强化类型的判读一致性评价为优异(κ=0.82)。52% (29/56)小ICC表现为渐进型强化,36% (20/56)为稳定型强化,5%(3/56)为快进快出型强化,7%(4/56)为快进+衰退型强化。直径<20 mm病灶最常见的强化类型为稳定型强化,20~30 mm病灶最常见为渐进型强化,小ICC的强化类型与病灶直径具有相关性(P=0.006)。

结论

合并肝硬化的小ICC强化类型主要为稳定型和渐进型,但少部分表现为快进快出的强化特征,此类型与小肝癌强化类似,为两者鉴别诊断的重点和难点。

Objective

To investigate the MRI enhancement features and differential diagnosis of small intrahepatic cholangiocarcinoma (ICC) combined with liver cirrhosis.

Methods

A total of 56 patients with small ICC combined with liver cirrhosis who underwent surgical treatment in the Eastern Hepatobiliary Surgery Hospital Affiliated to the Second Military Medical University between December 2012 and December 2015 were enrolled in this prospective cohort study. Among them, 40 cases were male and 16 were female, age 29-74 years old with a median age of 54 years old. The informed consents of all patients were obtained and the local ethical committee approval was received. All the patient underwent hepatic dynamic enhanced MRI examination and intravenous injection of Gd-DTPA contrast. The enhanced MRI imaging included hepatic arterial phase, portal vein phase and delayed phase. Inter-observer consistency of determining enhancement types was assessed by kappa coefficient. Correlation between enhancement type and lesion diameter was analyzed by Fisher's exact probability test.

Results

The inter-observer consistency of determing lesion enhancement types was excellent (κ=0.82). 52%(29/56) of the patients with small ICC presented as progressive enhancement pattern, 36%(20/56) as stable pattern, 5%(3/56) as fast-in and fast-out pattern and 7%(4/56) as fast-in + recession pattern. The most common enhancement pattern for the lesions with a diameter of less than 20 mm was stable pattern, and progressive pattern for the lesions with a diameter of 20-30 mm. The enhancement pattern of small ICC was correlated with the diameter of lesion (P=0.006).

Conclusions

Most common MRI enhancement pattern for the patients with small ICC combined with liver cirrhosis are stable and progressive pattern. But some presents as fast-in and fast-out pattern, and this pattern is similar to that of small hepatocellular carcinoma, which is the key and difficult point for differential diagnosis between them.

表1 肝脏增强MRI技术参数
表2 肝内胆管细胞癌直径与动态强化类型的关系(例)
[1]
Zhang H, Yang T, Wu M, et al. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management[J]. Cancer Lett, 2016, 379(2):198-205.
[2]
Razumilava N, Gores GJ. Cholangiocarcinoma[J]. Lancet, 2014, 383(9935):2168-2179.
[3]
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6):1268-1289.
[4]
Patel T. Cholangiocarcinoma--controversies and challenges[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(4):189-200.
[5]
Zhou H, Wang H, Zhou D, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis[J]. Eur J Cancer, 2010, 46(6):1056-1061.
[6]
Peng NF, Li LQ, Qin X, et al. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus[J]. Ann Surg Oncol, 2011, 18(5):1258-1266.
[7]
Jeong S, Tong Y, Sha M, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Oncotarget, 2017, 8(10):17292-17300.
[8]
Li R, Cai P, Ma KS, et al. Dynamic enhancement patterns of intrahepatic cholangiocarcinoma in cirrhosis on contrast-enhanced computed tomography: risk of misdiagnosis as hepatocellular carcinoma[J]. Sci Rep, 2016(6):26772.
[9]
Fujita N, Asayama Y, Nishie A, et al. Mass-forming intrahepatic cholangiocarcinoma: enhancement patterns in the arterial phase of dynamic hepatic CT-correlation with clinicopathological findings[J]. Eur Radiol, 2017, 27(2):498-506.
[10]
Koh J, Chung YE, Nahm JH, et al. Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI[J]. Eur Radiol, 2016, 26(2):407-416.
[11]
Huang B, Wu L, Lu XY, et al. Small intrahepatic cholangiocarcinoma and hepatocellular carcinoma in cirrhotic livers may share similar enhancement patterns at multiphase dynamic MR imaging[J]. Radiology, 2016, 281(1): 150-157.
[12]
Hwang J, Kim YK, Min JH, et al. Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI[J]. Eur Radiol, 2017, DOI: 10.1007/s00330-017-4846-4[Epub ahead of print].
[13]
Kang Y, Lee JM, Kim SH, et al. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images[J]. Radiology, 2012, 264(3):751-760.
[14]
Kim SA, Lee JM, Lee KB, et al. Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern--correlation with clinicopathologic findings[J]. Radiology, 2011, 260(1):148-157.
[15]
Iavarone M, Piscaglia F, Vavassori S, et al. Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis[J]. J Hepatol, 2013, 58(6):1188-1193.
[16]
Rimola J, Forner A, Tremosini S, et al. Non-invasive diagnosis of hepatocellular carcinoma ≤2 cm in cirrhosis. diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI[J]. J Hepatol, 2012, 56(6):1317-1323.
[17]
Zhang N, Gu J, Yin L, et al. Incorporation of alpha-fetoprotein (AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database[J]. Oncotarget, 2016, 7(49):81389-81401.
[18]
Yoh T, Seo S, Hatano E, et al. A novel biomarker-based preoperative prognostic grading system for predicting survival after surgery for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2017, 24(5): 1351-1357.
[19]
Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: absence of contrast was hout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma[J]. Hepatology, 2009, 50(3):791-798.
[20]
Sheng RF, Zeng MS, Rao SX, et al. MRI of small intrahepatic mass-forming cholangiocarcinoma and atypical small hepatocellular carcinoma (≤3 cm) with cirrhosis and chronic viral hepatitis: a comparative study[J]. Clin Imaging, 2014, 38(3):265-272.
[1] 丁建民, 秦正义, 张翔, 周燕, 周洪雨, 王彦冬, 经翔. 超声造影与普美显磁共振成像对具有高危因素的≤3 cm肝结节进行LI-RADS分类诊断的前瞻性研究[J]. 中华医学超声杂志(电子版), 2023, 20(09): 930-938.
[2] 张莲莲, 惠品晶, 丁亚芳. 颈部血管超声在粥样硬化斑块易损性评估中的应用价值[J]. 中华医学超声杂志(电子版), 2023, 20(08): 816-821.
[3] 董晓燕, 赵琪, 唐军, 张莉, 杨晓燕, 李姣. 奥密克戎变异株感染所致新型冠状病毒感染疾病新生儿的临床特征分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 595-603.
[4] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[5] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[6] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[7] 潘冰, 吕少诚, 赵昕, 李立新, 郎韧, 贺强. 淋巴结清扫数目对远端胆管癌胰十二指肠切除手术疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 608-612.
[8] 韩宇, 张武, 李安琪, 陈文颖, 谢斯栋. MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 669-673.
[9] 李斌奎. 不可切除肝内胆管细胞癌的转化治疗[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 511-516.
[10] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[11] 秦维, 王丹, 孙玉, 霍玉玲, 祝素平, 郑艳丽, 薛瑞. 血清层粘连蛋白、Ⅳ型胶原蛋白对代偿期肝硬化食管胃静脉曲张出血的预测价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 447-451.
[12] 张雯, 宋牡丹, 邓雪婷, 张云. 强化营养支持辅助奥曲肽治疗肝硬化合并食管胃底静脉曲张破裂出血的疗效及再出血危险因素[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 456-460.
[13] 朱翔宇, 王建美, 张辉, 叶红英. 无创左心室压力-应变循环技术在左心室功能参数与肝硬化的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 494-498.
[14] 吴钰娴, 冯亚园, 霍雷, 贾宁阳, 张娟. 原发性肝脏淋巴瘤的影像学诊断价值研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 349-353.
[15] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
阅读次数
全文


摘要